News
CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...
Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback